nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—systemic lupus erythematosus—focal segmental glomerulosclerosis	0.447	1	CtDrD
Methotrexate—ALB—focal segmental glomerulosclerosis	0.113	1	CbGaD
Methotrexate—ABCC10—Cyclosporine—focal segmental glomerulosclerosis	0.0908	0.283	CbGbCtD
Methotrexate—ABCC3—Cyclosporine—focal segmental glomerulosclerosis	0.0571	0.178	CbGbCtD
Methotrexate—ABCC1—Cyclosporine—focal segmental glomerulosclerosis	0.0351	0.109	CbGbCtD
Methotrexate—SLCO1A2—Cyclosporine—focal segmental glomerulosclerosis	0.0313	0.0976	CbGbCtD
Methotrexate—SLCO1B1—Cyclosporine—focal segmental glomerulosclerosis	0.0295	0.0921	CbGbCtD
Methotrexate—ABCC2—Cyclosporine—focal segmental glomerulosclerosis	0.026	0.0809	CbGbCtD
Methotrexate—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.0235	0.0732	CbGbCtD
Methotrexate—SLC22A6—Cyclosporine—focal segmental glomerulosclerosis	0.019	0.0592	CbGbCtD
Methotrexate—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.00846	0.0264	CbGbCtD
Methotrexate—FOLR1—nephron—focal segmental glomerulosclerosis	0.00825	0.173	CbGeAlD
Methotrexate—Lung fibrosis interstitial—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.0768	CcSEcCtD
Methotrexate—SLCO3A1—nephron—focal segmental glomerulosclerosis	0.00341	0.0713	CbGeAlD
Methotrexate—Lymphoproliferative disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00334	0.0654	CcSEcCtD
Methotrexate—X-linked lymphoproliferative syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00334	0.0654	CcSEcCtD
Methotrexate—SLC22A8—nephron—focal segmental glomerulosclerosis	0.00212	0.0444	CbGeAlD
Methotrexate—Septicemia—Cyclosporine—focal segmental glomerulosclerosis	0.00199	0.039	CcSEcCtD
Methotrexate—FOLR1—nephron tubule—focal segmental glomerulosclerosis	0.00178	0.0373	CbGeAlD
Methotrexate—FOLR1—kidney—focal segmental glomerulosclerosis	0.00157	0.0327	CbGeAlD
Methotrexate—FOLR1—cortex of kidney—focal segmental glomerulosclerosis	0.00153	0.0319	CbGeAlD
Methotrexate—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.0253	CcSEcCtD
Methotrexate—Paresis—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.0243	CcSEcCtD
Methotrexate—GGH—nephron tubule—focal segmental glomerulosclerosis	0.00118	0.0248	CbGeAlD
Methotrexate—SLCO4C1—nephron tubule—focal segmental glomerulosclerosis	0.00105	0.022	CbGeAlD
Methotrexate—GGH—kidney—focal segmental glomerulosclerosis	0.00104	0.0218	CbGeAlD
Methotrexate—GGH—cortex of kidney—focal segmental glomerulosclerosis	0.00101	0.0212	CbGeAlD
Methotrexate—Bacterial infection—Cyclosporine—focal segmental glomerulosclerosis	0.000979	0.0192	CcSEcCtD
Methotrexate—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00095	0.0186	CcSEcCtD
Methotrexate—SLCO4C1—kidney—focal segmental glomerulosclerosis	0.000923	0.0193	CbGeAlD
Methotrexate—SLCO4C1—cortex of kidney—focal segmental glomerulosclerosis	0.000899	0.0188	CbGeAlD
Methotrexate—FPGS—cortex of kidney—focal segmental glomerulosclerosis	0.000891	0.0186	CbGeAlD
Methotrexate—ATIC—kidney—focal segmental glomerulosclerosis	0.000885	0.0185	CbGeAlD
Methotrexate—Azotaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000849	0.0166	CcSEcCtD
Methotrexate—SLC22A11—nephron tubule—focal segmental glomerulosclerosis	0.000813	0.017	CbGeAlD
Methotrexate—Multiple fractures—Cyclosporine—focal segmental glomerulosclerosis	0.000778	0.0152	CcSEcCtD
Methotrexate—Fracture—Cyclosporine—focal segmental glomerulosclerosis	0.000778	0.0152	CcSEcCtD
Methotrexate—SLC22A6—nephron tubule—focal segmental glomerulosclerosis	0.000766	0.016	CbGeAlD
Methotrexate—Vaginal discharge—Cyclosporine—focal segmental glomerulosclerosis	0.000743	0.0145	CcSEcCtD
Methotrexate—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.000743	0.0145	CcSEcCtD
Methotrexate—SLCO1C1—kidney—focal segmental glomerulosclerosis	0.000736	0.0154	CbGeAlD
Methotrexate—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.000719	0.0141	CcSEcCtD
Methotrexate—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.000719	0.0141	CcSEcCtD
Methotrexate—SLC22A11—kidney—focal segmental glomerulosclerosis	0.000715	0.0149	CbGeAlD
Methotrexate—Encephalopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000704	0.0138	CcSEcCtD
Methotrexate—SLC22A7—kidney—focal segmental glomerulosclerosis	0.000697	0.0146	CbGeAlD
Methotrexate—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000697	0.0136	CcSEcCtD
Methotrexate—SLC22A11—cortex of kidney—focal segmental glomerulosclerosis	0.000696	0.0146	CbGeAlD
Methotrexate—TYMS—nephron tubule—focal segmental glomerulosclerosis	0.000683	0.0143	CbGeAlD
Methotrexate—SLC22A7—cortex of kidney—focal segmental glomerulosclerosis	0.000679	0.0142	CbGeAlD
Methotrexate—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.000676	0.0132	CcSEcCtD
Methotrexate—DHFR—nephron tubule—focal segmental glomerulosclerosis	0.000676	0.0141	CbGeAlD
Methotrexate—SLC22A6—cortex of kidney—focal segmental glomerulosclerosis	0.000656	0.0137	CbGeAlD
Methotrexate—Burning sensation—Cyclosporine—focal segmental glomerulosclerosis	0.000651	0.0127	CcSEcCtD
Methotrexate—PGD—nephron tubule—focal segmental glomerulosclerosis	0.00065	0.0136	CbGeAlD
Methotrexate—SLCO3A1—kidney—focal segmental glomerulosclerosis	0.000647	0.0135	CbGeAlD
Methotrexate—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.000639	0.0125	CcSEcCtD
Methotrexate—SLCO3A1—cortex of kidney—focal segmental glomerulosclerosis	0.00063	0.0132	CbGeAlD
Methotrexate—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.0006	0.0118	CcSEcCtD
Methotrexate—DHFR—kidney—focal segmental glomerulosclerosis	0.000594	0.0124	CbGeAlD
Methotrexate—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.000586	0.0115	CcSEcCtD
Methotrexate—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.000586	0.0115	CcSEcCtD
Methotrexate—TYMS—cortex of kidney—focal segmental glomerulosclerosis	0.000584	0.0122	CbGeAlD
Methotrexate—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.000581	0.0114	CcSEcCtD
Methotrexate—DHFR—cortex of kidney—focal segmental glomerulosclerosis	0.000579	0.0121	CbGeAlD
Methotrexate—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000576	0.0113	CcSEcCtD
Methotrexate—AOX1—nephron tubule—focal segmental glomerulosclerosis	0.000573	0.012	CbGeAlD
Methotrexate—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.000571	0.0112	CcSEcCtD
Methotrexate—PGD—kidney—focal segmental glomerulosclerosis	0.000571	0.0119	CbGeAlD
Methotrexate—PGD—cortex of kidney—focal segmental glomerulosclerosis	0.000556	0.0116	CbGeAlD
Methotrexate—SLC16A1—kidney—focal segmental glomerulosclerosis	0.000533	0.0112	CbGeAlD
Methotrexate—SLCO1B1—kidney—focal segmental glomerulosclerosis	0.000519	0.0108	CbGeAlD
Methotrexate—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.000504	0.00986	CcSEcCtD
Methotrexate—AOX1—kidney—focal segmental glomerulosclerosis	0.000503	0.0105	CbGeAlD
Methotrexate—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000497	0.00973	CcSEcCtD
Methotrexate—ABCC3—kidney—focal segmental glomerulosclerosis	0.000492	0.0103	CbGeAlD
Methotrexate—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.000491	0.0096	CcSEcCtD
Methotrexate—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.000491	0.0096	CcSEcCtD
Methotrexate—AOX1—cortex of kidney—focal segmental glomerulosclerosis	0.00049	0.0102	CbGeAlD
Methotrexate—ABCC10—kidney—focal segmental glomerulosclerosis	0.00049	0.0102	CbGeAlD
Methotrexate—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000487	0.00954	CcSEcCtD
Methotrexate—ABCC10—cortex of kidney—focal segmental glomerulosclerosis	0.000477	0.00997	CbGeAlD
Methotrexate—ABCC4—nephron tubule—focal segmental glomerulosclerosis	0.000462	0.00967	CbGeAlD
Methotrexate—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00046	0.00901	CcSEcCtD
Methotrexate—SLC22A8—nephron tubule—focal segmental glomerulosclerosis	0.000459	0.00959	CbGeAlD
Methotrexate—ABCC2—nephron tubule—focal segmental glomerulosclerosis	0.000448	0.00936	CbGeAlD
Methotrexate—SLCO1A2—kidney—focal segmental glomerulosclerosis	0.000422	0.00883	CbGeAlD
Methotrexate—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.000413	0.00809	CcSEcCtD
Methotrexate—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.000409	0.008	CcSEcCtD
Methotrexate—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.000409	0.008	CcSEcCtD
Methotrexate—ABCC4—kidney—focal segmental glomerulosclerosis	0.000406	0.0085	CbGeAlD
Methotrexate—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.000405	0.00792	CcSEcCtD
Methotrexate—SLC22A8—kidney—focal segmental glomerulosclerosis	0.000403	0.00843	CbGeAlD
Methotrexate—ABCC4—cortex of kidney—focal segmental glomerulosclerosis	0.000396	0.00827	CbGeAlD
Methotrexate—ABCC2—kidney—focal segmental glomerulosclerosis	0.000393	0.00822	CbGeAlD
Methotrexate—SLC22A8—cortex of kidney—focal segmental glomerulosclerosis	0.000393	0.00821	CbGeAlD
Methotrexate—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.000392	0.00768	CcSEcCtD
Methotrexate—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000385	0.00753	CcSEcCtD
Methotrexate—ABCC2—cortex of kidney—focal segmental glomerulosclerosis	0.000383	0.00801	CbGeAlD
Methotrexate—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.000377	0.00738	CcSEcCtD
Methotrexate—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.000374	0.00731	CcSEcCtD
Methotrexate—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.000365	0.00715	CcSEcCtD
Methotrexate—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.000346	0.00678	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.000339	0.00664	CcSEcCtD
Methotrexate—ABCC1—cortex of kidney—focal segmental glomerulosclerosis	0.000337	0.00705	CbGeAlD
Methotrexate—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.000335	0.00655	CcSEcCtD
Methotrexate—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.000328	0.00642	CcSEcCtD
Methotrexate—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.000326	0.00682	CbGeAlD
Methotrexate—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.000311	0.00608	CcSEcCtD
Methotrexate—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000297	0.0058	CcSEcCtD
Methotrexate—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000278	0.00544	CcSEcCtD
Methotrexate—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000272	0.00532	CcSEcCtD
Methotrexate—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.000265	0.00519	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000264	0.00516	CcSEcCtD
Methotrexate—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000254	0.00498	CcSEcCtD
Methotrexate—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000253	0.00495	CcSEcCtD
Methotrexate—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000253	0.00495	CcSEcCtD
Methotrexate—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.000252	0.00494	CcSEcCtD
Methotrexate—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000249	0.00487	CcSEcCtD
Methotrexate—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000247	0.00482	CcSEcCtD
Methotrexate—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000246	0.00481	CcSEcCtD
Methotrexate—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000241	0.00472	CcSEcCtD
Methotrexate—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000239	0.00468	CcSEcCtD
Methotrexate—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000239	0.00467	CcSEcCtD
Methotrexate—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000228	0.00447	CcSEcCtD
Methotrexate—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000227	0.00444	CcSEcCtD
Methotrexate—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000227	0.00444	CcSEcCtD
Methotrexate—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000225	0.00441	CcSEcCtD
Methotrexate—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000224	0.00439	CcSEcCtD
Methotrexate—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000223	0.00436	CcSEcCtD
Methotrexate—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000219	0.00428	CcSEcCtD
Methotrexate—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000212	0.00414	CcSEcCtD
Methotrexate—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000206	0.00403	CcSEcCtD
Methotrexate—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000205	0.004	CcSEcCtD
Methotrexate—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000204	0.00399	CcSEcCtD
Methotrexate—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000201	0.00393	CcSEcCtD
Methotrexate—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000199	0.00389	CcSEcCtD
Methotrexate—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000198	0.00387	CcSEcCtD
Methotrexate—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000194	0.00379	CcSEcCtD
Methotrexate—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000186	0.00365	CcSEcCtD
Methotrexate—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000183	0.00359	CcSEcCtD
Methotrexate—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000183	0.00358	CcSEcCtD
Methotrexate—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000178	0.00349	CcSEcCtD
Methotrexate—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000178	0.00348	CcSEcCtD
Methotrexate—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000177	0.00346	CcSEcCtD
Methotrexate—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000172	0.00338	CcSEcCtD
Methotrexate—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000171	0.00335	CcSEcCtD
Methotrexate—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00329	CcSEcCtD
Methotrexate—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00329	CcSEcCtD
Methotrexate—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00329	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000167	0.00327	CcSEcCtD
Methotrexate—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000166	0.00325	CcSEcCtD
Methotrexate—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000163	0.00318	CcSEcCtD
Methotrexate—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000161	0.00316	CcSEcCtD
Methotrexate—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000161	0.00336	CbGeAlD
Methotrexate—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00016	0.00314	CcSEcCtD
Methotrexate—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000158	0.0031	CcSEcCtD
Methotrexate—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000158	0.00309	CcSEcCtD
Methotrexate—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000157	0.00307	CcSEcCtD
Methotrexate—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000156	0.00305	CcSEcCtD
Methotrexate—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00301	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000147	0.00288	CcSEcCtD
Methotrexate—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000146	0.00286	CcSEcCtD
Methotrexate—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000145	0.00283	CcSEcCtD
Methotrexate—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000144	0.00281	CcSEcCtD
Methotrexate—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000143	0.00281	CcSEcCtD
Methotrexate—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.00278	CcSEcCtD
Methotrexate—ABCB1—kidney—focal segmental glomerulosclerosis	0.000141	0.00296	CbGeAlD
Methotrexate—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00014	0.00274	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000139	0.00273	CcSEcCtD
Methotrexate—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000139	0.00272	CcSEcCtD
Methotrexate—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000138	0.0027	CcSEcCtD
Methotrexate—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000138	0.00288	CbGeAlD
Methotrexate—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000133	0.0026	CcSEcCtD
Methotrexate—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000132	0.00258	CcSEcCtD
Methotrexate—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000128	0.00251	CcSEcCtD
Methotrexate—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000128	0.0025	CcSEcCtD
Methotrexate—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000128	0.0025	CcSEcCtD
Methotrexate—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000119	0.00233	CcSEcCtD
Methotrexate—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000116	0.00226	CcSEcCtD
Methotrexate—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000114	0.00223	CcSEcCtD
Methotrexate—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00011	0.00216	CcSEcCtD
Methotrexate—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000107	0.00209	CcSEcCtD
Methotrexate—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000103	0.00201	CcSEcCtD
Methotrexate—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000102	0.00199	CcSEcCtD
Methotrexate—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000102	0.00199	CcSEcCtD
Methotrexate—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000101	0.00198	CcSEcCtD
Methotrexate—Nausea—Cyclosporine—focal segmental glomerulosclerosis	9.58e-05	0.00188	CcSEcCtD
Methotrexate—TYMS—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	3.33e-05	0.00163	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.31e-05	0.00162	CbGpPWpGaD
Methotrexate—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	3.26e-05	0.0016	CbGpPWpGaD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.22e-05	0.00158	CbGpPWpGaD
Methotrexate—FPGS—Disease—LPL—focal segmental glomerulosclerosis	3.22e-05	0.00157	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—LPL—focal segmental glomerulosclerosis	3.17e-05	0.00155	CbGpPWpGaD
Methotrexate—PGD—Metabolism—LIPC—focal segmental glomerulosclerosis	3.14e-05	0.00154	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.06e-05	0.0015	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—CTGF—focal segmental glomerulosclerosis	3.03e-05	0.00148	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TRPC6—focal segmental glomerulosclerosis	3e-05	0.00147	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	2.99e-05	0.00147	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.99e-05	0.00146	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	2.98e-05	0.00146	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—NOS2—focal segmental glomerulosclerosis	2.95e-05	0.00145	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—FN1—focal segmental glomerulosclerosis	2.95e-05	0.00144	CbGpPWpGaD
Methotrexate—ABCC10—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.94e-05	0.00144	CbGpPWpGaD
Methotrexate—SLC46A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.94e-05	0.00144	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.92e-05	0.00143	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	2.89e-05	0.00141	CbGpPWpGaD
Methotrexate—SLC22A11—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	2.88e-05	0.00141	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	2.86e-05	0.0014	CbGpPWpGaD
Methotrexate—SLC16A1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	2.83e-05	0.00138	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	2.83e-05	0.00138	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	2.81e-05	0.00137	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.79e-05	0.00137	CbGpPWpGaD
Methotrexate—SLCO3A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.79e-05	0.00136	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CTGF—focal segmental glomerulosclerosis	2.77e-05	0.00136	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.76e-05	0.00135	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—PCNA—focal segmental glomerulosclerosis	2.72e-05	0.00133	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AGT—focal segmental glomerulosclerosis	2.71e-05	0.00133	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.7e-05	0.00132	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—LPL—focal segmental glomerulosclerosis	2.69e-05	0.00132	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—LPL—focal segmental glomerulosclerosis	2.69e-05	0.00132	CbGpPWpGaD
Methotrexate—SLCO4C1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.66e-05	0.0013	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.63e-05	0.00129	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	2.63e-05	0.00129	CbGpPWpGaD
Methotrexate—SLC22A7—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	2.61e-05	0.00128	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.6e-05	0.00127	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.59e-05	0.00127	CbGpPWpGaD
Methotrexate—PGD—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.55e-05	0.00125	CbGpPWpGaD
Methotrexate—FPGS—Disease—NOS2—focal segmental glomerulosclerosis	2.51e-05	0.00123	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	2.51e-05	0.00123	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—LPL—focal segmental glomerulosclerosis	2.5e-05	0.00123	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—GNAQ—focal segmental glomerulosclerosis	2.5e-05	0.00123	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—SERPINE1—focal segmental glomerulosclerosis	2.49e-05	0.00122	CbGpPWpGaD
Methotrexate—SLCO1B3—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	2.48e-05	0.00122	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	2.45e-05	0.0012	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—PCNA—focal segmental glomerulosclerosis	2.43e-05	0.00119	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	2.4e-05	0.00118	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.4e-05	0.00118	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	2.4e-05	0.00117	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—PCNA—focal segmental glomerulosclerosis	2.38e-05	0.00116	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.34e-05	0.00115	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	2.34e-05	0.00114	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AGT—focal segmental glomerulosclerosis	2.3e-05	0.00113	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AGT—focal segmental glomerulosclerosis	2.3e-05	0.00113	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.29e-05	0.00112	CbGpPWpGaD
Methotrexate—PGD—Disease—LPL—focal segmental glomerulosclerosis	2.29e-05	0.00112	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	2.27e-05	0.00111	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.26e-05	0.00111	CbGpPWpGaD
Methotrexate—ABCC3—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	2.25e-05	0.0011	CbGpPWpGaD
Methotrexate—SLCO1C1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.23e-05	0.00109	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.23e-05	0.00109	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	2.2e-05	0.00108	CbGpPWpGaD
Methotrexate—SLC22A8—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	2.2e-05	0.00108	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	2.19e-05	0.00107	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.19e-05	0.00107	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.16e-05	0.00106	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—PCNA—focal segmental glomerulosclerosis	2.12e-05	0.00104	CbGpPWpGaD
Methotrexate—FPGS—Disease—SERPINE1—focal segmental glomerulosclerosis	2.11e-05	0.00104	CbGpPWpGaD
Methotrexate—ABCC4—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	2.11e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—LPL—focal segmental glomerulosclerosis	2.1e-05	0.00103	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—ALB—focal segmental glomerulosclerosis	2.08e-05	0.00102	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—LIPC—focal segmental glomerulosclerosis	2.07e-05	0.00102	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.06e-05	0.00101	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.05e-05	0.00101	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.03e-05	0.000992	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.02e-05	0.00099	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—FN1—focal segmental glomerulosclerosis	2e-05	0.000978	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.97e-05	0.000966	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.96e-05	0.00096	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NOS2—focal segmental glomerulosclerosis	1.96e-05	0.000958	CbGpPWpGaD
Methotrexate—SLCO1A2—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	1.95e-05	0.000955	CbGpPWpGaD
Methotrexate—PGD—Metabolism—LPL—focal segmental glomerulosclerosis	1.92e-05	0.000939	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	1.9e-05	0.000931	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	1.89e-05	0.000926	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—LIPC—focal segmental glomerulosclerosis	1.84e-05	0.000902	CbGpPWpGaD
Methotrexate—SLC22A6—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	1.83e-05	0.000898	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CTGF—focal segmental glomerulosclerosis	1.83e-05	0.000894	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.82e-05	0.000893	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AGT—focal segmental glomerulosclerosis	1.79e-05	0.000879	CbGpPWpGaD
Methotrexate—PGD—Disease—NOS2—focal segmental glomerulosclerosis	1.79e-05	0.000876	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.78e-05	0.000873	CbGpPWpGaD
Methotrexate—ABCC2—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	1.78e-05	0.000873	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—ALB—focal segmental glomerulosclerosis	1.77e-05	0.000866	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—ALB—focal segmental glomerulosclerosis	1.77e-05	0.000866	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.73e-05	0.000847	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.68e-05	0.000824	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.68e-05	0.000822	CbGpPWpGaD
Methotrexate—SLCO1B1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	1.67e-05	0.000817	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.66e-05	0.000814	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—ALB—focal segmental glomerulosclerosis	1.66e-05	0.000812	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—SERPINE1—focal segmental glomerulosclerosis	1.65e-05	0.000807	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.64e-05	0.000805	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AGT—focal segmental glomerulosclerosis	1.64e-05	0.000804	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CTGF—focal segmental glomerulosclerosis	1.62e-05	0.000795	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—LIPC—focal segmental glomerulosclerosis	1.61e-05	0.000787	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.59e-05	0.000778	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—TGFB1—focal segmental glomerulosclerosis	1.57e-05	0.000769	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.56e-05	0.000764	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	1.55e-05	0.000758	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	1.52e-05	0.000743	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	1.51e-05	0.000741	CbGpPWpGaD
Methotrexate—MTHFR—Disease—LPL—focal segmental glomerulosclerosis	1.51e-05	0.00074	CbGpPWpGaD
Methotrexate—PGD—Disease—SERPINE1—focal segmental glomerulosclerosis	1.51e-05	0.000738	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.5e-05	0.000732	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—FN1—focal segmental glomerulosclerosis	1.49e-05	0.000729	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.48e-05	0.000724	CbGpPWpGaD
Methotrexate—AOX1—Disease—LPL—focal segmental glomerulosclerosis	1.48e-05	0.000723	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—LIPC—focal segmental glomerulosclerosis	1.48e-05	0.000722	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	1.47e-05	0.000722	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.47e-05	0.00072	CbGpPWpGaD
Methotrexate—SLC22A11—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.46e-05	0.000717	CbGpPWpGaD
Methotrexate—SLC16A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.44e-05	0.000703	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.43e-05	0.0007	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CTGF—focal segmental glomerulosclerosis	1.42e-05	0.000693	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—ALB—focal segmental glomerulosclerosis	1.38e-05	0.000674	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	1.37e-05	0.000671	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.36e-05	0.000667	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.36e-05	0.000665	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.36e-05	0.000665	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	1.36e-05	0.000664	CbGpPWpGaD
Methotrexate—DHFR—Disease—LPL—focal segmental glomerulosclerosis	1.34e-05	0.000658	CbGpPWpGaD
Methotrexate—FPGS—Disease—TGFB1—focal segmental glomerulosclerosis	1.34e-05	0.000654	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—LIPC—focal segmental glomerulosclerosis	1.33e-05	0.000652	CbGpPWpGaD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.33e-05	0.000651	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.33e-05	0.00065	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	1.31e-05	0.00064	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.3e-05	0.000639	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CTGF—focal segmental glomerulosclerosis	1.3e-05	0.000636	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.27e-05	0.000623	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—LPL—focal segmental glomerulosclerosis	1.27e-05	0.00062	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.26e-05	0.000618	CbGpPWpGaD
Methotrexate—PGD—Metabolism—ALB—focal segmental glomerulosclerosis	1.26e-05	0.000617	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.24e-05	0.000607	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ALB—focal segmental glomerulosclerosis	1.24e-05	0.000606	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—LPL—focal segmental glomerulosclerosis	1.24e-05	0.000605	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.22e-05	0.000599	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.2e-05	0.000586	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.2e-05	0.000586	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NOS2—focal segmental glomerulosclerosis	1.18e-05	0.000578	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	1.17e-05	0.000575	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CTGF—focal segmental glomerulosclerosis	1.17e-05	0.000574	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.16e-05	0.000569	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.16e-05	0.000568	CbGpPWpGaD
Methotrexate—AOX1—Disease—NOS2—focal segmental glomerulosclerosis	1.15e-05	0.000565	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.14e-05	0.000558	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	1.13e-05	0.000555	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—LPL—focal segmental glomerulosclerosis	1.12e-05	0.000551	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.12e-05	0.000548	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.12e-05	0.000547	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	1.09e-05	0.000533	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AGT—focal segmental glomerulosclerosis	1.08e-05	0.00053	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.08e-05	0.000529	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.07e-05	0.000524	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AGT—focal segmental glomerulosclerosis	1.06e-05	0.000518	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.05e-05	0.000514	CbGpPWpGaD
Methotrexate—DHFR—Disease—NOS2—focal segmental glomerulosclerosis	1.05e-05	0.000514	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.04e-05	0.000511	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.04e-05	0.000511	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TGFB1—focal segmental glomerulosclerosis	1.04e-05	0.000509	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	1.03e-05	0.000503	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—LPL—focal segmental glomerulosclerosis	1.02e-05	0.000502	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	1.02e-05	0.0005	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SERPINE1—focal segmental glomerulosclerosis	9.94e-06	0.000487	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	9.92e-06	0.000485	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—LIPC—focal segmental glomerulosclerosis	9.91e-06	0.000485	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—LPL—focal segmental glomerulosclerosis	9.82e-06	0.000481	CbGpPWpGaD
Methotrexate—AOX1—Disease—SERPINE1—focal segmental glomerulosclerosis	9.71e-06	0.000475	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AGT—focal segmental glomerulosclerosis	9.62e-06	0.000471	CbGpPWpGaD
Methotrexate—PGD—Disease—TGFB1—focal segmental glomerulosclerosis	9.51e-06	0.000466	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.4e-06	0.00046	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	9.38e-06	0.000459	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	9.32e-06	0.000456	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CTGF—focal segmental glomerulosclerosis	9.18e-06	0.00045	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	9.18e-06	0.000449	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	9.03e-06	0.000442	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—LPL—focal segmental glomerulosclerosis	9e-06	0.000441	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	8.92e-06	0.000437	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	8.92e-06	0.000437	CbGpPWpGaD
Methotrexate—DHFR—Disease—SERPINE1—focal segmental glomerulosclerosis	8.83e-06	0.000433	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AGT—focal segmental glomerulosclerosis	8.76e-06	0.000429	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CTGF—focal segmental glomerulosclerosis	8.73e-06	0.000427	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	8.48e-06	0.000415	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.46e-06	0.000414	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AGT—focal segmental glomerulosclerosis	8.4e-06	0.000411	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ALB—focal segmental glomerulosclerosis	8.31e-06	0.000407	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—LPL—focal segmental glomerulosclerosis	8.12e-06	0.000398	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ALB—focal segmental glomerulosclerosis	8.12e-06	0.000397	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	8.08e-06	0.000396	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GNAQ—focal segmental glomerulosclerosis	8.04e-06	0.000394	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	7.85e-06	0.000384	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TGFB1—focal segmental glomerulosclerosis	7.82e-06	0.000383	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	7.76e-06	0.00038	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AGT—focal segmental glomerulosclerosis	7.7e-06	0.000377	CbGpPWpGaD
Methotrexate—ABCC1—Disease—LPL—focal segmental glomerulosclerosis	7.6e-06	0.000372	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.45e-06	0.000365	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ALB—focal segmental glomerulosclerosis	7.38e-06	0.000362	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—LPL—focal segmental glomerulosclerosis	7.07e-06	0.000346	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AGT—focal segmental glomerulosclerosis	6.95e-06	0.00034	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	6.87e-06	0.000336	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	6.76e-06	0.000331	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	6.74e-06	0.00033	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ALB—focal segmental glomerulosclerosis	6.73e-06	0.000329	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	6.66e-06	0.000326	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	6.64e-06	0.000325	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ALB—focal segmental glomerulosclerosis	6.44e-06	0.000315	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—LPL—focal segmental glomerulosclerosis	6.37e-06	0.000312	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—focal segmental glomerulosclerosis	6.28e-06	0.000307	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—focal segmental glomerulosclerosis	6.13e-06	0.0003	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AGT—focal segmental glomerulosclerosis	6.05e-06	0.000296	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—LPL—focal segmental glomerulosclerosis	6.05e-06	0.000296	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS2—focal segmental glomerulosclerosis	5.94e-06	0.000291	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—focal segmental glomerulosclerosis	5.91e-06	0.000289	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	5.66e-06	0.000277	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	5.61e-06	0.000275	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	5.6e-06	0.000274	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—focal segmental glomerulosclerosis	5.58e-06	0.000273	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AGT—focal segmental glomerulosclerosis	5.45e-06	0.000267	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—focal segmental glomerulosclerosis	5.33e-06	0.000261	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AGT—focal segmental glomerulosclerosis	5.18e-06	0.000253	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SERPINE1—focal segmental glomerulosclerosis	5e-06	0.000245	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	4.99e-06	0.000244	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	4.96e-06	0.000243	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	4.79e-06	0.000235	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—focal segmental glomerulosclerosis	4.64e-06	0.000227	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.59e-06	0.000225	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	4.37e-06	0.000214	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	4.24e-06	0.000208	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—focal segmental glomerulosclerosis	4.18e-06	0.000205	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.03e-06	0.000197	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—focal segmental glomerulosclerosis	3.97e-06	0.000194	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	3.68e-06	0.00018	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	3.54e-06	0.000173	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	3.46e-06	0.000169	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—focal segmental glomerulosclerosis	3.16e-06	0.000155	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	3.03e-06	0.000148	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	2.96e-06	0.000145	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	2.59e-06	0.000127	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	1.99e-06	9.73e-05	CbGpPWpGaD
